0      0

26th Napa Pain Conference

NPC26-Sa6-C - Osteoarthritis


Aug 17, 2019 4:00pm ‐ Aug 17, 2019 5:30pm


Description


Osteoarthritis



Target Audience: Clinicians treating patients with osteoarthritis and researchers studying the effects and treatments for OA


Learning Objectives

As a result of participating in this activity, learners will be better able to:

  • Utilize pharmacologic and non-pharmacologic treatment options for the management of osteoarthritis

Presentations

Treating Osteoarthritis Today

B. Todd Sitzman, MD

Where vs Why: Central Contributions to Regional Pain Conditions

Roger B. Fillingim, PhD


Description

Osteoarthritis is the most common form of arthritis, and pain is its defining symptom. Osteoarthritis is a complex disease whose etiology bridges biomechanics and biochemistry. Available treatment options, of which NSAIDs are the most common, often provide inadequate relief and are associated with health risks when used long term.

Evidence is growing for the role of systemic factors (such as genetics, dietary intake, estrogen use, and bone density) and of local biomechanical factors (such as muscle weakness, obesity, and joint laxity). Clinical investigations are uncovering the correlation with structural changes in the joint and insights into the efficacy of new analgesics and the pathophysiology of OA pain.



Additional Reading

  • Felson, D. T., Lawrence, R. C., Dieppe, P. A., Hirsch, R., Helmick, C. G., Jordan, J. M., ... & Sowers, M. (2000). Osteoarthritis: new insights. Part 1: the disease and its risk factors. Annals of Internal Medicine, 133(8), 635-646.
  • Cottam, W. J., Condon, L., Alshuft, H., Reckziegel, D., & Auer, D. P. (2016). Associations of limbic-affective brain activity and severity of ongoing chronic arthritis pain are explained by trait anxiety. NeuroImage: Clinical, 12, 269-276.
  • Ishikawa, G., Koya, Y., Tanaka, H., & Nagakura, Y. (2015). Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis. Osteoarthritis and Cartilage, 23(6), 925-932.
  • Lane, N. E. (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. The Journal of Rheumatology. Supplement, 49, 20-24.
  • Calich, A. L. G., Domiciano, D. S., & Fuller, R. (2010). Osteoarthritis: can anti-cytokine therapy play a role in treatment?. Clinical Rheumatology, 29(5), 451-455.
  • Felson, D. T., Lawrence, R. C., Hochberg, M. C., McAlindon, T., Dieppe, P. A., Minor, M. A., ... & Lorig, K. R. (2000). Osteoarthritis: new insights. Part 2: treatment approaches. Annals of Internal Medicine, 133(9), 726-737.
  • Wolfe, F., Zhao, S., & Lane, N. (2000). Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 43(2), 378-385.
  • Reckziegel, D., Raschke, F., Cottam, W. J., & Auer, D. P. (2016). Cingulate GABA levels inversely correlate with the intensity of ongoing chronic knee osteoarthritis pain. Molecular Pain, 12, 1744806916650690.
  • Malfait, A. M., & Schnitzer, T. J. (2013). Towards a mechanism-based approach to pain management in osteoarthritis. Nature Reviews Rheumatology, 9(11), 654.
  • Atchia, I., Kane, D., Reed, M. R., Isaacs, J. D., & Birrell, F. (2011). Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Annals of the Rheumatic Diseases, 70(1), 110-116.

Speaker(s):

  • Dr. B. Todd Sitzman, MD, MPH, Medical Director, Advanced Pain Therapy, PLLC
  • Roger B. Fillingim, PhD, Distinguished Professor & Director, University of Florida, Pain Research and Intervention Center of Excellence

You must be logged in and own this session in order to post comments.